Key result
Combining RAAS inhibitors with SGLT2 and GLP-1 inhibitors provides effective management for diabetic nephropathy.
Why the study?
Standard treatments provide only partial relief when used late in diabetic nephropathy, prompting the need to evaluate novel treatment options and biomarkers.
Design
Narrative review
Authors
Loading...
Supports combined RAS-SGLT2/GLP-1 use in diabetic nephropathy; leaves open optimal regimens and outcomes in prospective RCTs.
Novel therapies, particularly the combination of SGLT2 inhibitors and RAAS blockers, provide more effective strategies for slowing the progression of diabetic kidney disease compared to traditional monotherapies.
Pillai et al. (2023) conducted a review in Diabetic Nephropathy. New treatment options (e.g., SGLT2 inhibitors, GLP-1 inhibitors, RAAS blockers) was evaluated. Renin-angiotensin system inhibitors combined with newer hypoglycemic drugs like SGLT2 and GLP-1 inhibitors provide effective therapeutic strategies for managing diabetic nephropathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: